Drug intelligence / Profile preview

antithrombin III

Development stage
Approved
Lead developer
Grifols
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Antithrombin III is a naturally occurring plasma protein and the major endogenous inhibitor of thrombin and other serine proteases in the coagulation cascade, including factors IXa, Xa, XIa, XIIa, plasmin, and kallikrein. It is synthesized in the liver and circulates at a concentration of about 12.5 mg/dL in healthy adults. Antithrombin exerts its anticoagulant effect by forming an irreversible complex with thrombin via interaction between the active serine site on thrombin and an arginine reactive site on antithrombin. This process is greatly accelerated by heparin; thus, heparin’s therapeutic effect depends on sufficient levels of functional antithrombin[2][3][4][9]. Antithrombin III concentrates are used as replacement therapy for patients with hereditary deficiency to prevent or treat venous thromboembolism during high-risk situations such as surgery or childbirth[1][3][5]. There are both plasma-derived (e.g., Thrombate III) and recombinant (e.g., ATryn) formulations available.

Brand names
Thrombate IIIATryn
Other names
antithrombinantithrombin (human)human antithrombin IIIplasma-derived antithrombin III
02

Targets

F10 (Factor Xa)F2 (Thrombin)FXIIa (Coagulation Factor XIIa)Factor XIaCoagulation Factor IXa

Beyond the preview

Go deeper on antithrombin III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on antithrombin III.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call